Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated.

Over 40 companies are working on more than 50 therapies for severe asthma. The severe asthma market is growing due to a ...

Asthma in early childhood could be linked to memory deficits, according to a new UC Davis study. (Getty Images ... Research ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

It has previously modelled peak sales for the new drug of around £3 billion a year. A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after ...

“Childhood is a period of rapid improvement in memory and, more generally, cognition. In children with asthma that ...

Childhood asthma may lead to memory difficulties, with early onset worsening these deficits, a UC Davis study finds. A new ...

Tezspire's 2021 approval in severe asthma represents a rapidly growing ... Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...

This study highlights the benefits of anti-inflammatory inhalers in asthma management, showing reduced complications and ...